Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy
CP1 is an uropathogenic Escherichia coli previously shown to promote inflammation and progression to prostate cancer. Here the authors show that in the context of a fully developed prostate cancer, CP1 promotes T cell infiltration into the tumour and increases the efficacy of anti-PD1 immunotherapy.
Guardado en:
Autores principales: | Jonathan F. Anker, Anum F. Naseem, Hanlin Mok, Anthony J. Schaeffer, Sarki A. Abdulkadir, Praveen Thumbikat |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3bf73253b2574b74bdc59f395c2f2af5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Bmi1 marks distinct castration-resistant luminal progenitor cells competent for prostate regeneration and tumour initiation
por: Young A. Yoo, et al.
Publicado: (2016) -
Facet Joint Injection versus Radiofrequency Facet Neurotomy for Treatment of Lumbar Facet Joint Arthropathy
por: Ahmed Faisal Toubar, PhD.,, et al.
Publicado: (2018) -
A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells.
por: Meejeon Roh, et al.
Publicado: (2008) -
Green nanotechnology of MGF-AuNPs for immunomodulatory intervention in prostate cancer therapy
por: Menka Khoobchandani, et al.
Publicado: (2021) -
Simple and effective bacterial-based intratumoral cancer immunotherapy
por: Teresa Neeman, et al.
Publicado: (2021)